Aurobindo receives FDA nod for generic Gilenya
Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis.
Aurobindo has received the Food and Drug Administration’s clearance for Fingolimod Capsules, 0.5mg, which are a generic of Novartis Pharmaceuticals’ Gilenya.
Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability.
[Read more: Aurobindo receives FDA OK for generic Emflaza]
Fingolimod Capsules had a market value of $483 million for the 12 months ending December 2023, per IQVIA.